Global Gestational Diabetes Market Size, Share, and COVID-19 Impact Analysis, By Diagnosis Type (Oral Glucose Tolerance Test, Fasting Blood Sugar Test, Random Blood Sugar Test, and Haemoglobin A1c Test), By Treatment Type (Dietary Changes, Insulin Therapy, Oral Medications, and Physical Activity), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 - 2035.

Global Gestational Diabetes Market  Size Insights Forecasts to 2035

• The Global Gestational Diabetes Market Size Was Estimated at USD 1.94 Billion in 2024
• The Market Size is Expected to Grow at a CAGR of around 5.37% from 2025 to 2035
• The Worldwide Gestational Diabetes Market Size is Expected to Reach USD 3.45 Billion by 2035
• Asia Pacific is expected to grow the fastest during the forecast period.

According to a research report published by Spherical Insights and Consulting, The Global Gestational Diabetes Market Size Was Worth Around USD 1.94 Billion In 2024 And Is Predicted To Grow To Around USD 3.45 Billion By 2035 With A Compound Annual Growth Rate (CAGR) Of 5.37% From 2025 And 2035. The market for gestational diabetes has a number of opportunities to grow due to the upsurging advancement in gestational diabetes mellitus screening and exercise therapy for gestational diabetes mellitus.

Market Overview

The Global Gestational Diabetes is rapidly growing owing to an increasing obesity rate, maternal age, and better diagnostic screening. The market further encompasses the diagnosis (glucose tests), management (diet, insulin, drugs), and monitoring devices, with dietary management being the largest segment. Gestational diabetes is a type of high blood sugar (glucose) that is first diagnosed during pregnancy, typically in the second or third trimester, and occurs when pregnancy-related hormonal changes cause insulin resistance, and the pancreas cannot produce enough insulin to overcome it. Gestational diabetes causes high blood sugar that can affect a pregnancy and a baby's health. Glycemic monitoring and insulin delivery are dramatically changing with CGM and insulin pump technologies, along with the use of nutrition-focused mobile applications for diabetes mellitus education.

Innovation and market expansion are anticipated as a result of major players' growing R&D expenditures, partnerships & collaborations, and awareness campaigns. For instance, in August 2025, the Gates Foundation is investing $2.5 billion in research and development (R&D) on women’s health over the next five years, focusing primarily on maternal care and sexual health.    

Report Coverage

This research report categorizes the Gestational Diabetes market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Gestational Diabetes market. Recent market developments and competitive strategies such as expansion, type launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Gestational Diabetes market. 

Driving Factors

The Global Gestational Diabetes Market Size is primarily driven by increasing advancements in medical technology, like continuous glucose monitors and mobile health apps. Furthermore, an increase in healthcare expenditure, policy changes & healthcare reforms, along with the growing prevalence of gestational diabetes, significantly contribute to escalating market growth of gestational diabetes. Additionally, the launch of several initiatives by the government for encouraging pregnant women to undergo screening tests and avoiding possible complications is contributing to promoting the market. Further, integration of artificial intelligence in the diagnosis and monitoring, as well as novel therapeutic innovations and management strategies, is anticipated to drive the market.

Restraining Factors

The Global Gestational Diabetes Market Size is restricted by factors like the high expense of insulin therapies and monitoring devices. Further, limited awareness and concerns associated with overdiagnosis and overtreatment of gestational diabetes are challenging the market growth.

Market Segmentation

The gestational diabetes market share is classified into diagnosis type and treatment type.  

• The oral glucose tolerance test segment dominated the market with the largest share of over 45.0% in 2024 and is projected to grow at a substantial CAGR during the forecast period.

Based on the diagnosis type, The Global Gestational Diabetes Market Size is divided into oral glucose tolerance test, fasting blood sugar test, random blood sugar test, and haemoglobin A1c test. Among these, the oral glucose tolerance test segment dominated the market with the largest share in 2024 and is projected to grow at a substantial CAGR during the forecast period. An oral glucose tolerance test is a routine part of prenatal care that checks how your body processes sugar. The widespread usage of OGTT for diagnosis due to its reliability is propelling the segmental market expansion.

The dietary changes segment accounted for the dominant market share of about 28.5% in 2024 and is anticipated to grow at a significant CAGR during the forecast period.

Based on the treatment type, the gestational diabetes market is divided into dietary changes, insulin therapy, oral medications, and physical activity. Among these, the dietary changes segment accounted for the dominant market share of about 28.5% in 2024 and is anticipated to grow at a significant CAGR during the forecast period. The segment includes lifestyle interventions, like nutritional modifications for managing blood glucose levels. Key strategies includes prioritizing high-fiber, low-GI foods, pairing carbs with protein/healthy fats, and avoiding sugary, processed foods.

Regional Segment Analysis of the Gestational Diabetes Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the gestational diabetes market over the predicted timeframe.

North America is anticipated to hold the largest share of about 37.0% in the gestational diabetes market over the predicted timeframe. The market ecosystem in North America is strong, due to shift towards non-invasive, tech-enabled management, personalized medicine, and integrated digital care. The demand for gestational diabetes has been driven by the region's growing prevalence of obesity, advanced maternal age, and sedentary lifestyles. Well-known North American businesses have played a significant role in propelling the market's expansion. For instance, in July 2024, the American Diabetes Association collaborated with the CVS Health Foundation to improve maternal health outcomes. The U.S. is leading the North America gestational diabetes market, driven by high screening, adoption of advanced technology, and reliance on insulin.

Asia Pacific is expected to grow at a rapid CAGR of about 10.0% in the gestational diabetes market during the forecast period. The Asia Pacific area has a thriving market for gestational diabetes due to its growing obesity rates, sedentary lifestyles, and growing urbanization in nations like China and India. Launching government guidelines for gestational diabetes has become a major driving factor in the market. For instance, the WHO launched global guidelines on diabetes during pregnancy on World Diabetes Day. China is a dominant country in the Asia Pacific region for the gestational diabetes market, owing to a large population base, increased rates of obesity, and an increased number of the maternal population.  

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Gestational Diabetes market, along with a comparative evaluation primarily based on their type of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes type development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Abbott Laboratories
• Roche Diagnostics
• Becton Dickinson and Company
• Medtronic
• Dexcom
• Ascensia Diabetes Care
• Sanofi
• Novo Nordisk
• Johnson & Johnson
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Development

• In January 2026, Wellcome Leap and Medicines360 launched a partnership last week that aims to accelerate maternal health tools globally. San Diego-based Wellcome Leap helps build and fund programs to improve human health. San Francisco-based Medicines360, meanwhile, is an innovation organization that helps develop and launch products for women.

• In March 2025, US pharma major Eli Lilly launched the much-awaited diabetes and obesity management drug Mounjaro in India at one-fifth of the US price.

• In March 2023, Abbott announced that the U.S. Food and Drug Administration (FDA) had cleared its FreeStyle Libre 2 and FreeStyle Libre 3 integrated continuous glucose monitoring (iCGM) system sensors for integration with automated insulin delivery (AID) systems.  

• In March 2023, Eli Lilly and Company announced price reductions of 70% for its most commonly prescribed insulins and an expansion of its Insulin Value Program that caps patient out-of-pocket costs at $35 or less per month.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the gestational diabetes market based on the below-mentioned segments:  

Global Gestational Diabetes Market, By Diagnosis Type

• Oral Glucose Tolerance Test
• Fasting Blood Sugar Test
• Random Blood Sugar Test
• Haemoglobin A1c Test

Global Gestational Diabetes Market, By Treatment Type

• Dietary Changes
• Insulin Therapy
• Oral Medications
• Physical Activity

Global Gestational Diabetes Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico

• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific

• South America
  • Brazil
  • Argentina
  • Rest of South America

• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa